Core Viewpoint - The current revenue share from AI business for Rongke Technology is low, attributed to industry development patterns and the company's product R&D and market advancement pace, rather than a significant shortfall in commercialization capability [2] Group 1: AI Business Development - The AI business is still in the strategic investment and market expansion phase, with a product matrix that includes AI medical record quality control, severe illness intelligent agents, and DRG/DIP medical insurance cost control systems [2] - The company plans to continue increasing R&D investment in AI and leverage its existing customer base in medical institutions to accelerate business scale expansion [2]

Core Viewpoint - The company is committed to deepening its presence in the smart health sector, leveraging artificial intelligence and computing power to enhance healthcare and urban management services [1][2] Group 1: Business Overview - The company has developed a comprehensive intelligent solution covering pre-hospital emergency, clinical diagnosis, and logistics management in the smart healthcare field, serving over 5,000 medical institutions and more than 80% of the top 100 hospitals [1] - In the smart city and energy management sectors, the company utilizes digital twin and edge computing technologies to create platforms like "Rongjia Houqin™" for energy control and safety operations in urban governance [1] Group 2: Financial Performance - In the first half of 2025, the company reported revenue of 292 million yuan, a year-on-year decrease of 7.01%, and a net loss of 272.29 million yuan, with losses expanding by 576.78% compared to the previous year [2] - For the first nine months of 2025, the company achieved revenue of 162 million yuan, a year-on-year decline of 4.49%, and a net loss of 446.11 million yuan, with losses increasing by 378.82% year-on-year [2]